Loading...
•
Mar 31, 2024
Paysign Q1 2024 Earnings Report
Paysign's financial performance saw revenue increase and adjusted EBITDA growth, driven by the patient affordability business.
Key Takeaways
Paysign reported a 30% increase in revenue and a 135% increase in adjusted EBITDA compared to the first quarter of the previous year. The patient affordability business grew significantly, with a 305% rise in revenue, becoming a major growth driver for the company. The company confirmed its full-year revenue guidance to be in the range of $54.5 million to $56.7 million and adjusted EBITDA to be in the range of $8.0 million to $9.0 million.
Revenue increased by 30% compared to Q1 2023.
Adjusted EBITDA grew by 135% compared to Q1 2023.
Patient affordability business revenue increased by 305% compared to Q1 2023.
Gross profit margins improved due to the shift to a greater percentage of pharma revenue.
Revenue by Segment
Forward Guidance
The company is confirming the guidance they gave in March, for total revenues to be in the range of $54.5 million to $56.7 million and adjusted EBITDA to be in the range of $8.0 million to $9.0 million.
Positive Outlook
- Total revenues to be in the range of $54.5 million to $56.7 million.
- Adjusted EBITDA to be in the range of $8.0 million to $9.0 million.
- Total revenue for Q2 2024 is expected to increase by approximately 27.5% over Q2 2023.
- Pharma revenue accounting for approximately 18.0% of the total revenue for Q2.
- Adjusted EBITDA for Q2 is expected to increase 65.0% to 70.0% from Q2 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...